Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels by Santini, V. et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ilal20
Leukemia & Lymphoma
ISSN: 1042-8194 (Print) 1029-2403 (Online) Journal homepage: https://www.tandfonline.com/loi/ilal20
Achievement of red blood cell transfusion
independence in red blood cell transfusion-
dependent patients with lower-risk non-del(5q)
myelodysplastic syndromes correlates with serum
erythropoietin levels
Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Barry Skikne, CL
Beach, Jerry Weaver, Nora Tu & Pierre Fenaux
To cite this article: Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Barry Skikne, CL
Beach, Jerry Weaver, Nora Tu & Pierre Fenaux (2020) Achievement of red blood cell transfusion
independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q)
myelodysplastic syndromes correlates with serum erythropoietin levels, Leukemia & Lymphoma,
61:6, 1475-1483, DOI: 10.1080/10428194.2020.1719088
To link to this article:  https://doi.org/10.1080/10428194.2020.1719088
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 17 Feb 2020. Submit your article to this journal 
Article views: 458 View related articles 
View Crossmark data
ORIGINAL ARTICLE
Achievement of red blood cell transfusion independence in red blood cell
transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic
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ABSTRACT
In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell
transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-
del(5q) myelodysplastic syndromes (MDS) ineligible for or refractory to erythropoiesis-stimulating
agents. To determine the influence of erythropoietin (EPO) level on response, 155 patients treated
with lenalidomide in MDS-005 were categorized into four groups by baseline EPO level. The EPO
>500mU/mL group had higher RBC transfusion burden and the lowest proportion of patients with
ring sideroblasts 15% versus lower EPO groups. Achievement of RBC-TI 8weeks inversely corre-
lated with EPO level, ranging from 42.5 to 15.5%. EPO level did not affect erythroid hematologic
improvement response (36.2–44.4%). This analysis suggests patients with lower EPO levels experi-
ence the strongest benefit from lenalidomide. Although meaningful improvements were observed
in some patients with EPO level >500mU/mL, new treatments are needed for this population.
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Myelodysplastic syndromes (MDS) are a group of
malignant bone marrow disorders that primarily affect
older adults and are characterized by anemia and
other cytopenias and an increased risk of transform-
ation to acute myeloid leukemia [1]. Marked disease
heterogeneity with regard to bone marrow morpho-
logic features as well as molecular and genetic charac-
teristics contributes to a highly variable natural
history. Risk stratification systems have been devel-
oped that help identify lower-risk patients with a rela-
tively good prognosis as well as higher-risk patients
for whom treatment with disease-modifying agents,
such as azacitidine and decitabine, may be warranted
[2–4]. Anemia is the most common cause of symp-
toms in patients with lower-risk MDS. However, the
underlying pathophysiology of anemia has not been
completely clarified, especially in characterizing the
abnormalities in the different MDS subtypes. To date,
the development of effective therapies for anemia in
MDS is still proceeding at a relatively slow pace.
For patients with lower-risk MDS, erythropoiesis-
stimulating agents (ESAs) are the first-line therapy,
provided that the serum erythropoietin (EPO) level is
500mU/mL [5,6]. With this approach, reported rates
of erythroid hematologic improvement (HI-E) achieve-
ment range from 15 to 63% [7–9] and median dura-
tions of response range from 7 to 28months [7,9]. Use
of luspatercept in patients with transfusion-dependent
lower-risk non-del(5q) MDS and prior ESA therapy has
been assessed [10,11]. In a phase 3 placebo-controlled
trial, 38% of patients treated with luspatercept
achieved red blood cell transfusion independence
(RBC-TI) 8weeks [11]. In patients with lower-risk
del(5q) MDS receiving 10mg lenalidomide, 56%
achieved RBC-TI [12].
In a randomized, placebo-controlled, phase 3 study
(MDS-005), the efficacy and safety of lenalidomide
(10mg) was evaluated in RBC transfusion-dependent
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(RBC-TD) patients with lower-risk non-del(5q) MDS
who were ineligible for or refractory to ESAs [13]. A
significantly higher proportion of patients treated with
lenalidomide achieved RBC-TI lasting 8weeks com-
pared with placebo (26.9 versus 2.5%; p< .001).
Factors that predicted response to lenalidomide
included low baseline EPO level (500mU/mL), prior
ESA use, and low transfusion burden (<4 RBC units/
28 days). Consistent with these results were those of a
study conducted in a comparable cohort of patients
with lower-risk MDS who were treated with the com-
bination of EPO and lenalidomide after having lost
response to ESAs alone [14].
In an effort to better characterize which non-
del(5q) patients are most likely to benefit from lenali-
domide therapy, we further explored the impact of
clinical characteristics, especially baseline EPO levels,
on response in patients treated with lenalidomide in
the MDS-005 study. These responses were then com-
pared with those reported in a previous randomized
study of patients with lower-risk MDS and del(5q)
(MDS-004).
Methods
Study design and treatment
Methodologies of the MDS-005 (NCT01029262) and
MDS-004 (NCT00179621) trials have been described in
detail elsewhere [12,13]. Briefly, MDS-005 was a
randomized, placebo-controlled, phase 3 study of
lenalidomide in RBC-TD patients with International
Prognostic Scoring System (IPSS) Low- or
Intermediate-1-risk MDS without del(5q) who were
ineligible for or refractory to ESAs [13]. Patients were
randomized 2:1 to oral lenalidomide 10mg once daily
or matching placebo once daily (both on 28-day
cycles); patients with creatinine clearance 40–60mL/
min received lenalidomide 5mg once daily. If patients
achieved RBC-TI 8weeks or erythroid response by
week 24, double-blind treatment continued until
erythroid relapse, disease progression, unacceptable
toxicity, or consent withdrawal. MDS-004 was a
randomized, placebo-controlled, phase 3 study of
lenalidomide (10 or 5mg/day) in RBC-TD patients with
IPSS Low- or Intermediate-1-risk MDS and del(5q) [12].
Statistical analysis
The current analyses were based on patients who
were randomized to lenalidomide and received at
least one dose of study treatment. EPO levels were
measured prior to randomization by a central
laboratory, and patients with missing baseline EPO
data were excluded from the analysis. Baseline charac-
teristics and efficacy endpoints were analyzed accord-
ing to baseline EPO level. For MDS-005, the following
baseline EPO level groups were analyzed: 100, >100
to 200, >200 to 500, and >500mU/mL. These
were referred to as the EPO 100, EPO 100–200, EPO
200–500, and EPO >500 groups, respectively. For
MDS-004, the following baseline EPO level groups
were analyzed: 200, >200 to 500, and >500mU/
mL; the lower end cutoff of 200 rather than 100mU/
mL was used due to the relatively small number of
patients with EPO 100. Demographic and baseline
characteristics were summarized using summary statis-
tics. For continuous variables, summary statistics
included number, mean, standard deviation, median,
minimum, and maximum. For categorical variables,
number and percentage were calculated.
Univariate and multivariate analyses were per-
formed for clinical characteristics predictive of
response. Efficacy endpoints were summarized using
summary statistics. For MDS-005, efficacy endpoints
included rate of RBC-TI 8weeks (primary endpoint);
rate of RBC-TI 24weeks; duration of RBC-TI; rate of
HI-E using International Working Group (IWG) 2006 cri-
teria [15]; rate of 4 RBC units transfusion reduction
(based on 8-week and 16-week assessment periods);
rate of 50% reduction in RBC units transfused; and
cytogenetic response. HI-E was defined as a hemoglo-
bin increase by 1.5 g/dL or reduction in transfusion
of 4 RBC units over 8weeks versus pretreatment.
Cytogenetic response was evaluated by conventional
metaphase cytogenetic analysis according to IWG
2006 criteria [15]. For MDS-004, efficacy endpoints
included rate of RBC-TI 26 weeks (primary endpoint);
time to RBC-TI 26weeks; duration of RBC-TI; rate of
HI-E using IWG 2000 criteria [16]; time to HI-E; and
duration of HI-E.




Of the 160 patients randomized to lenalidomide in
MDS-005, 155 (96.9%) had baseline EPO data available
and were included in the analysis. The number of
patients in the EPO 100, 100–200, 200–500, and
>500 groups were 40 (25.8%), 27 (17.4%), 30 (19.4%),
and 58 (37.4%), respectively. Baseline demographics
and disease characteristics according to EPO level are
shown in Table 1. Median age was 71 years overall
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Mean (SD) 73.1 (8.06) 70.3 (6.87) 70.2 (8.46) 67.7 (7.83)
Median (range) 75.0 (53.0–86.0) 70.0 (55.0–83.0) 72.0 (46.0–85.0) 68.0 (53.0–81.0)
Male, n (%) 18 (45.0) 17 (63.0) 22 (73.3) 48 (82.8)
Time since diagnosis, years
Mean (SD) 5.8 (5.47) 4.4 (3.83) 4.7 (4.65) 2.8 (4.07)
Median (range) 4.3 (0.6–24.2) 2.6 (0.8–13.9) 4.4 (0.5–23.9) 2.2 (0.1–29.6)
RBC transfusion burden, units/28 days
Mean (SD) 3.0 (0.99) 3.2 (1.12) 3.1 (0.91) 3.9 (1.44)
Median (range) 2.8 (1.8–6.5) 3.0 (1.8–6.3) 3.0 (2.0–5.8) 3.8 (1.8–8.8)
IPSS risk category, n (%)
Low 19 (47.5) 20 (74.1) 12 (40.0) 32 (55.2)
Intermediate-1 21 (52.5) 7 (25.9) 18 (60.0) 26 (44.8)
IPSS karyotype, n (%)
Good 32 (80.0) 23 (85.2) 25 (83.3) 48 (82.8)
Intermediate 8 (20.0) 4 (14.8) 4 (13.3) 10 (17.2)
Missing 0 0 1 (3.3) 0
WHO 2008 classification, n (%)
RA 0 0 1 (3.3) 5 (8.6)
RARS 2 (5.0) 2 (7.4) 4 (13.3) 3 (5.2)
RCMD 32 (80.0) 24 (88.9) 19 (63.3) 37 (63.8)
RAEB-1 6 (15.0) 1 (3.7) 6 (20.0) 13 (22.4)
Time from last ESAs to start of lenalidomide, days n ¼ 17 n ¼ 13 n ¼ 11 n ¼ 10
Mean (SD) 803.3 (1208.3) 517.6 (911.3) 444.3 (631.9) 229.3 (123.7)
Median (range) 276.0 (63.0–4850) 114.0 (58.0–3314) 255.0 (49.0–2216) 232.0 (56.0–452.0)
Prior MDS therapy, n (%) 40 (100) 27 (100) 28 (93.3) 35 (60.3)
Prior ESA treatment, n (%) 40 (100) 27 (100) 27 (90.0) 26 (44.8)
Prior G-CSF use, n (%) 8 (20.0) 6 (22.2) 7 (23.3) 3 (5.2)
Number of cytopenias, n (%)
0–1 28 (70.0) 17 (63.0) 16 (53.3) 36 (62.1)
2–3 12 (30.0) 10 (37.0) 14 (46.7) 22 (37.9)
Serum EPO level at screening, mU/mL
Mean (SD) 52.8 (25.43) 143.1 (27.95) 326.6 (82.06) 1835 (1658.6)
Median (range) 52.5 (6.0–95.0) 147.0 (102.0–193.0) 309.5 (206.0–495.0) 1166 (521.0–7600)
Ring sideroblast status, n (%)
<15% 5 (12.5) 2 (7.4) 8 (26.7) 38 (65.5)
15% (RARS and RCMD) 35 (87.5) 25 (92.6) 22 (73.3) 20 (34.5)
Bone marrow blast percentage
Mean (SD) 3.1 (1.85) 2.2 (1.55) 3.1 (2.20) 3.3 (1.99)
Median (range) 2.8 (0.5–8.5) 2.0 (0.0–5.0) 3.0 (0.0–9.5) 3.3 (0.0–8.5)
Bone marrow blast count, n (%)
<5% 34 (85.0) 26 (96.3) 24 (80.0) 45 (77.6)
5% 6 (15.0) 1 (3.7) 6 (20.0) 13 (22.4)
ANC,  109/L
Mean (SD) 2.7 (1.42) 2.6 (1.31) 2.5 (2.20) 2.6 (1.65)
Median (range) 2.5 (0.6–6.4) 2.5 (0.5–6.8) 2.3 (0.6–12.2) 2.4 (0.5–7.7)
Platelet count,  109/L
Mean (SD) 260.1 (123.94) 291.8 (113.20) 246.4 (118.66) 240.6 (154.48)
Median (range) 227.5 (69.0–579.0) 286.0 (63.0–588.0) 246.5 (51.0–496.0) 205.5 (43.0–746.0)
Hemoglobin, g/dL
Mean (SD) 8.9 (1.08) 9.1 (1.10) 8.7 (1.25) 8.4 (1.36)
Median (range) 8.6 (7.3–12.3) 9.0 (7.3–11.7) 8.8 (6.1–11.1) 8.2 (5.5–11.3)
Creatinine clearance, mL/min
Mean (SD) 69.2 (23.73) 81.1 (24.34) 82.7 (25.05) 89.8 (28.46)
Median (range) 61.3 (37.8–130.4) 82.0 (40.9–141.5) 79.0 (45.0–156.3) 88.1 (41.9–189.3)
Creatinine, mg/dL
Mean (SD) 0.9 (0.22) 0.9 (0.28) 0.9 (0.29) 0.9 (0.24)
Median (range) 0.9 (0.5–1.5) 0.9 (0.6–1.6) 0.8 (0.5–1.6) 0.9 (0.4–1.6)
Serum bilirubin, lmol/L
Mean (SD) 20.1 (13.92) 20.8 (15.54) 16.5 (6.95) 14.4 (9.57)
Median (range) 17.0 (3.0–62.0) 15.0 (7.0–70.0) 16.0 (5.0–33.0) 12.0 (4.0–57.0)
LDH, mg/dL
Mean (SD) 191.2 (84.39) 200.2 (72.45) 203.9 (75.98) 195.0 (67.79)
Median (range) 180.0 (86.0–568.0) 190.0 (88.0–347.0) 199.0 (86.0–395.0) 190.5 (92.0–508.0)
ANC: absolute neutrophil count; del(5q): deletion 5q; EPO: erythropoietin; ESA: erythropoiesis-stimulating agent; G-CSF: granulocyte colony-stimulating
factor; IPSS: International Prognostic Scoring System; LDH: lactate dehydrogenase; MDS: myelodysplastic syndromes; RBC: red blood cell; RA: refractory
anemia; RAEB: refractory anemia with excess blasts; RARS: RA with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; SD: standard
deviation; WHO: World Health Organization.
aPercentages do not always add up to 100% due to rounding off.
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and ranged from 68 years in the EPO >500 group to
75 years in the EPO 100 group. The proportion of
patients who were male was 45% in the EPO 100
group, compared with 82.8% in the EPO >500 group.
Median creatinine clearance was 61.3mL/min in
the EPO 100 group, rising to 88.1mL/min in the EPO
>500 group; ANOVA revealed that this difference was
statistically significant (p¼ .0002).
Data regarding the time from the last dose of ESA
to start of lenalidomide therapy were available for 17,
13, 11, and 10 patients in the EPO 100, 100–200,
200–500, and >500 groups, respectively. The median
time from last ESA dose to start of lenalidomide was
longest in the EPO 100 group (276 days); median
time in the EPO 100–200, 200–500, and >500 groups
was 114, 255, and 232days, respectively (Table 1).
Notably, the MDS-005 study included a washout phase
of 56days before the start of lenalidomide to minim-
ize the effects of ESAs during lenalidomide treatment.
The EPO >500 group generally had poorer disease
characteristics at baseline. The median EPO level was
high (1166mU/mL; range 521–7600mU/mL) and com-
pared with other EPO groups, the EPO >500 group
had higher RBC transfusion burden (Table 1). The EPO
>500 group also had the shortest median time since
diagnosis (2.2 [range 0.1–29.6] versus 4.3 years
[0.6–24.2] in the EPO 100 group [p¼ .0013; ANOVA
test]), and the lowest proportion of patients with ring
sideroblasts (RS) 15%, at 34.5% of patients. Patients
with RS were those with the World Health
Organization (WHO)-defined MDS subtypes refractory
anemia with ring sideroblasts (RARS) or refractory
cytopenia with multilineage dysplasia (RCMD) who
had RS 15%.
Duration of lenalidomide treatment
The median duration of lenalidomide treatment was
comparable among EPO groups (Table 2) and ranged
from 151 days in the EPO 200–500 group to 169 days
in the EPO 100–200 group.
Response to lenalidomide
Achievement of RBC-TI 8weeks inversely correlated
with baseline EPO level, from 42.5% in the EPO 100
group to 15.5% in the EPO >500 group (Table 2;
Figure 1(A)). Notably, all patients who achieved RBC-TI
8weeks had received prior ESAs, with the exception
of three patients in the EPO >500 group. Median dur-
ation of RBC-TI 8weeks was longest in the EPO
100 group (326 days), compared with the EPO
100–200, 200–500, and >500 groups (145, 153, and
207 days, respectively; Table 2). However, 14 patients
with available baseline EPO data continue to receive
lenalidomide as of the cutoff date and data collection
for these patients is ongoing. Of these 14 patients,
five are baseline EPO 100, three are EPO 100–200,
two are EPO 200–500, and four are EPO >500.
Univariate and multivariate analysis of predictive
factors for RBC-TI 8weeks are presented in Table 3.
As previously assessed in the primary MDS-005 study











RBC-TI 8 weeks, n (%) 17 (42.5) 9 (33.3) 7 (23.3) 9 (15.5)
Duration of RBC-TI, daysa 326 145 153 207
RBC-TI 8 weeks by ring sideroblast status, n/N (%)
<15% 4/5 (80.0) 1/2 (50.0) 1/8 (12.5) 5/38 (13.2)
15% 13/35 (37.1) 8/25 (32.0) 6/22 (27.3) 4/20 (20.0)
RBC-TI 8 weeks by sex, n/N (%)
Female 8/22 (36.4) 5/10 (50.0) 4/8 (50.0) 2/10 (20.0)
Male 9/18 (50.0) 4/17 (23.5) 3/22 (13.6) 7/48 (14.6)
RBC-TI 24 weeks, n (%) 11 (27.5) 4 (14.8) 5 (16.7) 7 (12.1)
Cytogenetic response (IWG 2006), n (%) n ¼ 6 n ¼ 3 n ¼ 7 n ¼ 10
Complete response 1 (16.7) 1 (33.3) 3 (42.9) 0
Partial response 2 (33.3) 0 0 2 (20.0)
HI-E (IWG 2006), n (%) 17 (42.5) 12 (44.4) 11 (36.7) 21 (36.2)
50% reduction in RBC units transfused, n (%) 17 (42.5) 11 (40.7) 10 (33.3) 21 (36.2)
4 RBC units transfusion reduction
(8-week assessment), n (%)
16 (40.0) 10 (37.0) 10 (33.3) 20 (34.5)
4 RBC units transfusion reduction
(16-week assessment), n (%)
10 (25.0) 6 (22.2) 6 (20.0) 11 (19.0)
Duration of treatment, days
Mean (SD) 250.2 (265.54) 194.2 (142.37) 193.1 (186.96) 191.2 (210.34)
Median (range) 151.5 (14.0–1158) 169.0 (28.0–564.0) 151.0 (7.0–813.0) 162.0 (12.0–1101)
del(5q): deletion 5q; EPO: erythropoietin; HI-E: erythroid hematologic improvement; IWG: International Working Group; MDS: myelodysplastic syndromes;
RBC: red blood cell; RBC-TI: RBC transfusion independence; SD: standard deviation.
aResponding patients only, median duration of RBC-TI was estimated using Kaplan–Meier analysis.
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[13], the rate of RBC-TI  8weeks was higher in
women than men, at 38.0 versus 21.9% (OR 0.432
[95% CI, 0.210 to 0.893; p¼ .023).
The rate of RBC-TI 8weeks was also higher in
patients with RS 15% than in those with RS <15%
(30.4 [31/102] versus 20.8% [11/53]), although no stat-
istical comparison was made for these subgroups. For
patients with RS 15%, consistent rates of RBC-TI
8weeks (20.0–37.1%) were seen across the EPO
groups; however, response rates varied considerably in
patients with RS <15% and no clear pattern emerged
when analyzed according to baseline EPO level
(Figure 2(A)). This may have been due to the limited
number of patients in each EPO subgroup.
A plateau was seen regarding the relationship
between baseline EPO level and RBC-TI 24weeks
(Table 2; Figure 1(B)). The response rate was highest in
patients with baseline EPO 100 (27.5%) and was
roughly flat across other EPO groups, ranging
from 12.1 to 16.7%. There was no direct correlation
between EPO baseline level and achievement of HI-E.
Rates of HI-E, as defined by IWG 2006 criteria,
were high overall, ranging from 36.2% in the EPO
>500 group to 44.4% in the EPO 100–200 group
(Table 2; Figure 1(C)). Similarly, no association between
baseline EPO level and achievement of HI-E was
observed when analyzed according to RS status
(Figure 2(B)).
Cytogenetic response was evaluated in 6, 3, 7,
and 10 patients in the EPO 100, 100–200, 200–500,
and >500 groups, respectively. There was no
discernible pattern in response rates according to EPO
level, possibly due to the small number of evaluable
patients in each subgroup. Complete cytogenetic
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Figure 1. Rates of RBC-TI 8weeks (A), RBC-TI 24weeks (B),
and HI-E (C) according to baseline EPO level in lenalidomide-
treated patients with lower-risk non-del(5q) MDS. EPO: erythro-
poietin; HI-E: erythroid hematologic improvement; MDS: mye-
lodysplastic syndromes; RBC-TI: red blood cell transfusion
independence.
Table 3. Univariate and multivariate logistic regression analysis for RBC-TI 8weeks in lenalidomide-treated patients with lower-
risk non-del(5q) MDS (N¼ 160).
Variable







Age (65 versus >65 years) 1.29 (0.58–2.86) .53 1.86 (0.74–4.67) .19 – –
Sex (male versus female) 0.43 (0.21–0.89) .02 0.77 (0.33–1.80) .55 – –
Time since MDS diagnosis (<2 versus 2 years) 0.86 (0.41–1.81) .69 1.05 (0.46–2.40) .90 – –
Mean baseline transfusion burden (low versus high)b 2.99 (1.08–8.24) .03 2.72 (0.91–8.16) .07 2.59 (0.91–7.36) .07
Bone marrow blast count (<5 versus 5%) 0.85 (0.34–2.11) .72 0.87 (0.30–2.59) .81 – –
IPSS riskc (Int-1 versus Low) 1.44 (0.71–2.90) .31 1.44 (0.64–3.24) .38 – –
Prior G-CSF use (yes versus no) 2.17 (0.91–5.2) .08 2.22 (0.82–6.02) .12 – –
Serum EPO level, mU/mL
100 versus >500a 4.02 (1.56–10.38) .02 3.34 (1.11–10.04) .07 3.53 (1.35–9.24) .04
>100–200 versus >500 2.72 (0.93–7.94) .42 2.61 (0.80–8.53) .34 2.52 (0.85–7.44) .43
>200–500 versus >500 1.66 (0.55–5.00) .54 1.25 (0.38–4.09) .33 1.49 (0.49–4.55) .49
CI: confidence interval; del(5q): deletion 5q; EPO: erythropoietin; G-CSF: granulocyte colony stimulating factor; Int: Intermediate; IPSS: International
Prognostic Scoring System; MDS: myelodysplastic syndromes; RBC-TI: red blood cell transfusion independence.
aN¼ 155 patients.
bFor the European Union, Australia, and United States, Low is defined as <4 units/28 days and high as 4 units/28 days. For Japan, Low is defined as
<8 units/28 days and high as 8 units/28 days.
cInvestigator-assessed IPSS risk.
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42.9% (3/7), and 0% (0/10) of patients in the EPO
100, 100–200, 200–500, and >500 groups, respect-
ively. Partial cytogenetic response was seen in 33.3%
(2/6), 0% (0/3), 0% (0/7), and 20.0% (2/10) of patients,
respectively.
Influence of EPO level in patients with del(5q)
The relationship between baseline EPO level and
response to lenalidomide was also analyzed in a popu-
lation of patients with lower-risk del(5q) MDS, using
data from the MDS-004 study. In the MDS-004 study,
the median baseline EPO level of del(5q) patients
treated with lenalidomide was 902mU/mL (range
59.4–6113.0), compared with 297.0mU/mL (range
6.0–7600.0) for the non-del(5q) patients in MDS-005. Of
the 138 patients randomized to lenalidomide in MDS-
004, 73 (52.9%) had baseline EPO data available and
were included in the analysis. The number of patients
in the EPO 200, 200–500, and >500 groups was 15
(20.5%), 12 (16.4%), and 46 (63.0%), respectively.
Baseline demographics and disease characteristics
according to EPO level are shown in Table S1. The pro-
portion of patients who were male was comparable
among EPO groups and ranged from 16.7% in the EPO
200–500 group to 26.7% in the EPO 200 group.
Median creatinine clearance was 92.8mL/min in the
EPO 200 group, compared with 70.8mL/min in the
EPO >500 group.
No association between baseline EPO level and
response to lenalidomide was observed in patients
with del(5q) MDS (Supplementary Table S2); there
were low numbers of del(5q) patients in the EPO
200 and >200 to 500 groups.
Discussion
The MDS-005 trial is the first randomized trial to evalu-
ate lenalidomide in RBC-TD patients with lower-risk,
non-del(5q) MDS who were ineligible for or refractory
to ESAs. Results of this analysis indicate that patients
with lower EPO levels at baseline were more likely to
benefit from lenalidomide treatment, with 42.5% of
patients with EPO 100mU/mL achieving RBC-TI
8weeks. A higher baseline EPO level did not com-
pletely preclude a response: among patients with the
highest EPO levels (>500mU/mL), 15.5% achieved
RBC-TI  8weeks. Furthermore, nearly all patients who
achieved RBC-TI 8weeks had received prior ESAs.
Benefit in terms of HI-E was observed irrespective of
baseline EPO level.
Rates of RBC-TI 8weeks were higher in patients
with RS 15% versus those with RS <15%, although
no statistical comparison was made for these sub-
groups. Whereas RBC-TI 8weeks response rates var-
ied considerably among patients with RS <15%,
response rates were consistent across EPO groups for
patients with RS 15%. The significance of these find-
ings are limited by the relatively small number of
patients with RS <15% in each EPO subgroup. It is to
be noted that, because of their good prognosis and
long overall survival without progression, MDS-RS
patients who have lost response to ESAs tend to be
present in high numbers in experimental studies and
their ineffective erythropoiesis may be responsive to
certain erythropoietic stimulating agents; however,
these observations may warrant further investigation.
Baseline EPO level >500mU/mL was associated
with several factors linked to poor outcome, including
higher RBC transfusion burden and a lower proportion
of patients with RS 15%. Patients with EPO
>500mU/mL also had a shorter time since diagnosis,
likely due to their ineligibility for ESA treatment [17].
Recently, a higher EPO level at baseline was also asso-
ciated with a lower probability of RBC-TI response to
luspatercept [10], and it has been suggested that fail-
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Figure 2. Rates of RBC-TI 8weeks (A) and HI-E (B) by ring
sideroblast status according to baseline EPO level in lenalido-
mide-treated patients with lower-risk non-del(5q) MDS. EPO:
erythropoietin; HI-E: erythroid hematologic improvement; MDS:
myelodysplastic syndromes; RBC-TI: red blood cell transfusion
independence; RS: ring sideroblast.
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disease that defines a population of patients with
poor prognosis [18,19]. Use of ESAs is not recom-
mended for patients with EPO >500mU/mL due to
reduced frequency of response [17,20]. For these
patients, very limited treatment options are available
[5]. Based on the current study wherein responses did
occur with lenalidomide therapy in a small population
of patients with EPO levels >500mU/mL, this recom-
mendation may not necessarily encompass all non-
del(5q) patients with high EPO levels. Unfortunately,
the current study does not allow for further interroga-
tion of the data to establish signals that would prede-
termine possible responders.
HI-E was achieved in 36–44% of patients treated
with lenalidomide, and the probability of attaining
HI-E appeared to be independent of EPO level. In the
EPO >500 group, 36.2% achieved HI-E but only 15.5%
achieved RBC-TI 8weeks; this discrepancy may
reflect the challenge of achieving a stringent clinical
trial endpoint, such as RBC-TI 8weeks, in patients
with a high transfusion requirement and low hemo-
globin level at baseline. It is therefore important to
consider various measures of efficacy and response in
addition to RBC-TI when making therapeutic decisions
in these patients with limited treatment options.
RBC-TI 8weeks was independent from EPO levels at
baseline in patients who achieved transfusion inde-
pendence on lenalidomide treatment (Table 2).
The inverse correlation between baseline EPO level
and achievement of RBC-TI 8weeks observed in
patients treated with lenalidomide is consistent with
findings from other studies (Table 4). In a phase 2b
study evaluating the combination of lenalidomide and
EPO in 131 patients with ESA-refractory lower-risk
non-del(5q) MDS, baseline EPO <100U/L was signifi-
cantly associated with achieving HI-E (47 versus 21%
for patients with EPO 100U/L) [14]. Similarly, res-
ponders to lenalidomide monotherapy had a lower
baseline EPO level than nonresponders (255mU/mL
versus 870mU/mL; although not statistically signifi-
cant) in a study of 39 patients with lower-risk MDS
who had failed prior ESA therapy or had EPO
>500mU/mL [21]. Differences in patient populations
and trial design preclude direct comparison of
response rates achieved in various studies. These find-
ings suggest that the block in erythropoiesis may be
present at various levels of differentiation and that
stimulation and restoration of erythroid differentiation
in MDS may therefore be obtained via modulation of
different signaling pathways.
The activity of lenalidomide in patients with non-
del(5q) MDS is not fully understood but may be due
in part to enhancement of the EPO receptor signaling
pathway. MDS clones are characterized by impaired
EPO receptor signaling despite normal EPO receptor
membrane density [22]. A key determinant of EPO
receptor signaling capacity is the location of the EPO
receptor within lipid membrane rafts [23], which have
been shown to be deficient in MDS clones [24].
Exposure of erythroid progenitor cells to lenalidomide
enhanced lipid raft formation ex vivo, and this was
accompanied by accumulation of signaling-competent
JAK2/EPO receptor complexes and exclusion of the
phosphatase CD45 in the lipid raft fractions [24,25].
Lenalidomide has also been shown to inhibit CD45, a
negative regulator of EPO receptor signaling, which
may further potentiate EPO receptor signaling [24,26].
In patients with higher EPO levels, marked intrinsic






Treatment LEN (10mg/day  28d q4w)b versus placebo LEN (10mg/day  21d q4w) versus LENþ rhEPO (60,000
units/week)
Patients IPSS Low- or Internediate-1-risk, non-del(5q) MDS, RBC-TD,
ineligible for or refractory to ESAs
IPSS Low- or Internediate-1-risk, non-del(5q) MDS, RBC-TD,
refractory to ESAs
Primary endpoint RBC-TI 8 weeks HI-E (IWG 2006) after 4 treatment cycles
RBC-TI 8-week: 26.9% versus 2.5%; p< .001
24-week: 17.5% versus 0%; p< .001
8-week: LEN 13.8% versus LENþ EPO 24.2%; p ¼ .13
HI-E 21.8% versus 0%c 23.1% versus 39.4%; p¼ .044
Response by baseline
EPO level (mU/mL)
RBC-TI  8 weeks: HI-E (IWG 2006): RBC-TI: HI-E (IWG 2006)d:
100: 42.5%
>100 to 200: 33.3%
>200 to 500: 23.3%
>500: 15.5%
100: 42.5%
>100 to 200: 44.4%




del(5q): deletion 5q; ESA: erythropoiesis-stimulating agent; EPO: erythropoietin; GFM: Groupe Français des Myelodysplasies; HI-E: erythroid hematologic
improvement; LEN: lenalidomide; IPSS: International Prognostic Scoring System; IWG: International Working Group; MDS: myelodysplastic syndromes;
q4w: every 4 weeks; RBC: red blood cell; RBC-TD: RBC transfusion dependence; RBC-TI: RBC transfusion independence; rhEPO: recombinant human EPO.
aCross-trial comparisons are limited by differences in baseline characteristics and patient eligibility criteria.
bLEN 5mg for patients with creatinine clearance 40–60mL/min.
c4 RBC units reduction based on a 16-week assessment period.
dAnalysis was based on the combined LEN and LENþ EPO groups.
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defects in the EPO receptor signaling pathway may
explain why they are less responsive to lenalidomide.
Anemia may arise from defects in early or late-stage
erythropoiesis, the latter being EPO-independent
[27,28]. Patients whose anemia is caused by defects in
late-stage erythropoiesis may be less sensitive to the
erythropoietic-promoting effects of lenalidomide.
Correlation of response to lenalidomide with
endogenous EPO levels was assessed across all MDS
subtypes. No association between baseline EPO level
and response to lenalidomide was observed in
patients with del(5q). The del(5q) and non-del(5q) sub-
types represent genetically and phenotypically differ-
ent forms of MDS; the molecular mechanism
underlying the perturbation of erythropoiesis in
del(5q) MDS is profoundly different from that in non-
del(5q) MDS [29]. Responses to ESA therapy are more
likely to occur in non-del(5q) patients than del(5q)
patients; moreover, responses are likely to be of a lon-
ger duration in the former group [30]. Ineffective
erythropoiesis in del(5q) MDS arises from allelic dele-
tion of a number of genes within the commonly
deleted region of chromosome 5q that play critical
roles in cell replication [31,32]. Clones with del(5q) are
particularly susceptible to the cytotoxic effects of lena-
lidomide arising from cereblon-dependent degradation
of haplodeficient proteins [33].
The effects of lenalidomide on the EPO receptor
signaling provide a rationale for combining lenalido-
mide with ESAs. Clinical data indicate that lenalido-
mide may restore sensitivity to recombinant human
EPO (rhEPO) in EPO-refractory non-del(5q) patients. In
a recent phase 3 trial conducted by the ECOG-ACRIN
Cancer Research Group evaluating lenalidomide with
or without rhEPO in patients with lower-risk non-
del(5q) MDS refractory to rhEPO, combination therapy
induced a major erythroid response in 25.6% of
patients, compared with 9.9% with lenalidomide alone
(p¼ .015) [34]. Notably, CD45 isoform distribution was
a significant predictor of response to combination
therapy (p¼ .04).
Our results should be balanced against the inherent
limitations of the analysis, such as its post hoc nature
and the relatively small number of patients in each
subgroup based on EPO level. Despite its limitations,
this analysis provides some important insights on
which patients with transfusion-dependent, lower-risk,
non-del(5q) MDS who were ineligible for or refractory
to ESAs are most likely to respond to lenalidomide
therapy. We demonstrated an inverse correlation
between baseline EPO level and achievement of RBC-
TI 8weeks. The relationship between EPO level and
HI-E requires further exploration in future studies. For
patients with EPO >500mU/mL, responses to lenalido-
mide were observed (15.5% achieved RBC-TI 8weeks
and 36.2% achieved HI-E); however, more effective
treatment strategies for these patients remains an
important unmet medical need.
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